Did You Know...
...that several people are credited with the invention of the flush toilet? Most people have heard of Thomas Crapper (1837-1910), the sanitary engineer who invented the valve-and-siphon arrangement that made the modern toilet possible. Another claimant to "the throne" was British inventor Alexander Cumming who patented a toilet in 1775. Then there's a nameless Minoan (a native of ancient Crete) who lived 4,000 years ago who supposedly was ahead of his time and created the first flush toilet!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7259157 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. ... | 08/21/2007 |
| RE39696 | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity The invention discloses a human cyclooxygenase-2 cDNA, a human cyclooxygenase-2 and assays for preferentially and independently measuring cyclogenase-2 or cyclooxygenase-1 activity present in a given sample. ... | 06/19/2007 |
| 7220734 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejecti... | 05/22/2007 |
| 7205293 | Benodiazepine spirohydantoin CGRP receptor antagonists The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pha... | 04/17/2007 |
| 7205292 | CGRP receptor antagonists The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the ... | 04/17/2007 |
| 7202251 | Bicyclic anilide spirohydantoin CGRP receptor antagonists The present invention is directed to compounds of the formula: that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache... | 04/10/2007 |
| 7199154 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods... | 04/03/2007 |
| 7199142 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection... | 04/03/2007 |
| 7196113 | Lactam tachykinin receptor antagonists The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these ... | 03/27/2007 |
| 7196079 | Benzodiazepine CGRP receptor antagonists The present invention is directed to compounds of Formula I: (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonis... | 03/27/2007 |
| 7196095 | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis | 03/27/2007 |
| 7192954 | Monocyclic anilide spirohydantoin CGRP receptor antagonists The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pha... | 03/20/2007 |
| 7189722 | Aryl spirohydantoin CGRP receptor antagonists The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pha... | 03/13/2007 |
| 7169809 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encom... | 01/30/2007 |
| 7166614 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful ... | 01/23/2007 |
| 7163951 | N-biarylmethyl aminocycloalkanecarboxamide derivatives N-Biarylmethylaminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... | 01/16/2007 |
| 7153968 | 8-(biaryl)quinoline PDE4 inhibitors 8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis an... | 12/26/2006 |
| 7144896 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors 8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors. ... | 12/05/2006 |
| 7144913 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma. ... | 12/05/2006 |
| 7105507 | Cyclohexane derivatives and their use as therapeutic agents The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R | 09/12/2006 |
| 7105533 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators Phenyl compounds substituted with a fused-heterobicyclo moiety, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other disease... | 09/12/2006 |
| 7091380 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... | 08/15/2006 |
| 7087601 | Metabotropic glutamate receptor-5 modulators Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are ... | 08/08/2006 |
| 7060715 | Substituted pyridines as selective cyclooxygenase-2 inhibitors The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. | 06/13/2006 |
| 7053089 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. ... | 05/30/2006 |
| 7019022 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion. ... | 03/28/2006 |
| 7009055 | Preparation of Sulfonyl quinoline A dibromomethyl moiety is converted to a sulfonylmethyl moiety by treatment with a sulfinic acid salt. For example, (methyl-sulfonyl)methyl bromo-quinoline is prepared by the treatment of dibromomethyl bromo-quinoline with a sulfinic acid salt. ... | 03/07/2006 |
| 6960646 | Cyclic peptides as potent and selective melanocortin-4 receptors agonists Cyclic peptides of formula I are potent and selective agonists of melanocortin-4 receptors, and as such are useful research tool for the determination of the physiological roles of the MC-4 receptor, as well as for the diagnoses, treatment or prevention of disorders... | 11/01/2005 |
| 6953792 | Cyclohexyl derivatives and their use as therapeutic agents The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3 | 10/11/2005 |
| 6943180 | Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable... | 09/13/2005 |
| 6919343 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... | 07/19/2005 |
| 6919353 | Substituted 8-arylquinolune PDE4 inhibitors 8-arylquinolines of formula (I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arth... | 07/19/2005 |
| 6909002 | Method of preparing inhibitors of phosphodiesterase-4 In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula V, which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a me... | 06/21/2005 |
| 6908921 | Quinoxalinone derivatives as bradykinin B1 antagonists 2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... | 06/21/2005 |
| 6903075 | Heterocyclic amide compounds as cell adhesion inhibitors Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions an... | 06/07/2005 |
| 6858631 | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2)inhibitor. ... | 02/22/2005 |
| 6855708 | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable f... | 02/15/2005 |
| 6852727 | Benzimisazo[4,5-f]isoquinolinone derivatives Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. ... | 02/08/2005 |
| 6841564 | Tri-aryl-substituted-ethane PDE4 inhibitors Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors. ... | 01/11/2005 |
| 6835837 | Process for making substituted 8-arylquinolinium benzenesulfonate A substituted 8-aryl quinoline and its benzenesulfonic acid salt is synthesized. ... | 12/28/2004 |
